NEITHER CANCER NOR MYOSITIS ARE COMMON IN PATIENTS TESTING POSITIVE FOR TIF1. BY LINE IMMUNOBLOT ASSAY

被引：0
|
作者：
Troelnikov, Alexander [1 ,2 ]
Choo, Xin Jing [3 ]
Beroukas, Dimi [1 ]
Limaye, Vidya [3 ,4 ]
机构：
[1] SA Pathology, Immunopathol Dept, Adelaide, SA, Australia
[2] Flinders Univ S Australia, Adelaide, SA, Australia
[3] Univ Adelaide, Discipline Med, Adelaide, SA, Australia
[4] Royal Adelaide Hosp, Dept Rheumatol, Adelaide, SA, Australia
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2023年 / 41卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-42
引用
收藏
页码：455 / 455
页数：1
相关论文
共 50 条
  • [41] Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer
    M. K. Bos
    S. W. Lam
    G. Motta
    J. C. A. Helmijr
    C. M. Beaufort
    E. de Jonge
    J. W. M. Martens
    E. Boven
    M. P. H. M. Jansen
    A. Jager
    S. Sleijfer
    Breast Cancer Research and Treatment, 2023, 200 : 271 - 279
  • [42] Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer
    Bos, M. K.
    Lam, S. W.
    Motta, G.
    Helmijr, J. C. A.
    Beaufort, C. M.
    de Jonge, E.
    Martens, J. W. M.
    Boven, E.
    Jansen, M. P. H. M.
    Jager, A.
    Sleijfer, S.
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 200 (02) : 271 - 279
  • [43] The efficacy and safety of TQ-B3101 monotherapy in the first-line treatment in patients with ROS1-positive non-small cell lung cancer
    Lu, S.
    Pan, H.
    Wu, L.
    Yao, Y.
    He, J.
    Wang, Y.
    Wang, X.
    Wang, X.
    Cai, X.
    Yu, Y.
    Ma, Z.
    Min, X.
    Yang, Z.
    Cao, L.
    Yang, H.
    Shu, Y.
    Zhuang, W.
    Cang, S.
    Fang, J.
    Li, K.
    ANNALS OF ONCOLOGY, 2022, 33 : S31 - S31
  • [44] Evaluating serum thymidine kinase 1 in hormone receptor positive metastatic breast cancer patients receiving first line endocrine therapy in the SWOG S0226 trial
    Paoletti, Costanza
    Barlow, William E.
    Bergqvist, Mattias
    Mehta, Rita S.
    Gralow, Julie R.
    Hortobagyi, Gabriel N.
    Albain, Kathy S.
    Pusztai, Lajos
    Sharma, Priyanka
    Godwin, Andrew K.
    Thompson, Alastair M.
    Hayes, Daniel F.
    Rae, James
    CANCER RESEARCH, 2021, 81 (04)
  • [45] The Rochester Modified Magee Algorithm (RoMMA): A Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Multigene Assay Testing
    Numbere, Numbereye
    Moisini, Ioana
    Katerji, Hani
    Zhang, Huina
    Wang, Xi
    Hicks, David
    Turner, Bradley
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 172 - 173
  • [46] Analysis of Real-World PD-L1 Testing and PD-L1 IHC 28-8 and 22C3 Assay Concordance in Patients with Breast Cancer
    Prince, Emily
    Pratt, James
    Novotny, James
    Chizhevsky, Vladislav
    Ragheb, Josette William
    Huron, David
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 238 - 239
  • [47] Analysis of Real-World PD-L1 Testing and PD-L1 IHC 28-8 and 22C3 Assay Concordance in Patients with Breast Cancer
    Prince, Emily
    Pratt, James
    Novotny, James
    Chizhevsky, Vladislav
    Ragheb, Josette William
    Huron, David
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 238 - 239
  • [48] The Rochester Modified Magee Algorithm (RoMMA): A Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Multigene Assay Testing
    Numbere, Numbereye
    Moisini, Ioana
    Katerji, Hani
    Zhang, Huina
    Wang, Xi
    Hicks, David
    Turner, Bradley
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 172 - 173
  • [49] Clinical utility of comprehensive circulating tumor DNA (ctDNA) testing compared to standard-of-care (SoC) tissue testing in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts).
    Benavides, Manuel
    Alcaide, Julia
    Alvarez, Martina
    Torres, Esperanza
    Sevilla, Isabel
    Calle, Silvia Gil
    Reyna, Carmen
    Ales, Inmaculada
    Duran, Gema
    Wolman, Roberto
    Cazorla, Mireya
    Gallego, Pedro Jimenez
    Lopez, Irene
    Cantero, Alexandra
    Godoy, Ana
    Lanman, Richard B.
    Faull, Iris
    Odegaard, Justin
    Kim, Il Jin
    Alba, Emilio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [50] A phase II trial of trabectedin (T) in patients (pts) with HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC)
    Tedesco, K. L.
    Blum, J. L.
    Goncalves, A.
    Lubinski, J.
    Ben-Baruch, N.
    Osborne, C. R.
    Lardelli, P.
    Tercero, J. C.
    Holmes, F. A.
    Delaloge, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345